Privium Fund Management B.V. Raises Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Privium Fund Management B.V. boosted its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 1.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 250,744 shares of the company’s stock after purchasing an additional 3,477 shares during the quarter. Ionis Pharmaceuticals makes up 2.5% of Privium Fund Management B.V.’s portfolio, making the stock its 11th biggest position. Privium Fund Management B.V.’s holdings in Ionis Pharmaceuticals were worth $10,045,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Great Point Partners LLC purchased a new stake in shares of Ionis Pharmaceuticals in the 2nd quarter worth about $15,728,000. International Assets Investment Management LLC grew its holdings in Ionis Pharmaceuticals by 3,287.0% in the third quarter. International Assets Investment Management LLC now owns 328,772 shares of the company’s stock worth $13,171,000 after purchasing an additional 319,065 shares during the period. Logos Global Management LP purchased a new stake in Ionis Pharmaceuticals in the second quarter worth about $14,298,000. Zimmer Partners LP bought a new position in shares of Ionis Pharmaceuticals during the first quarter valued at approximately $11,718,000. Finally, Marshall Wace LLP lifted its holdings in shares of Ionis Pharmaceuticals by 1,021.5% during the second quarter. Marshall Wace LLP now owns 173,199 shares of the company’s stock valued at $8,255,000 after purchasing an additional 157,756 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Stock Up 1.9 %

Ionis Pharmaceuticals stock opened at $39.19 on Friday. Ionis Pharmaceuticals, Inc. has a one year low of $35.95 and a one year high of $54.44. The stock has a fifty day moving average of $40.65 and a 200 day moving average of $42.92. The company has a debt-to-equity ratio of 4.67, a quick ratio of 7.51 and a current ratio of 7.61. The stock has a market cap of $5.73 billion, a PE ratio of -16.06 and a beta of 0.39.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.21. The firm had revenue of $134.00 million during the quarter, compared to analyst estimates of $128.99 million. Ionis Pharmaceuticals had a negative net margin of 44.58% and a negative return on equity of 113.42%. As a group, sell-side analysts predict that Ionis Pharmaceuticals, Inc. will post -3.73 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on IONS. Leerink Partnrs raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 24th. The Goldman Sachs Group upped their price target on shares of Ionis Pharmaceuticals from $33.00 to $37.00 and gave the stock a “sell” rating in a research note on Friday, August 2nd. Bank of America increased their price objective on shares of Ionis Pharmaceuticals from $67.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. JPMorgan Chase & Co. lifted their target price on shares of Ionis Pharmaceuticals from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Finally, Leerink Partners upgraded shares of Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the company from $53.00 to $62.00 in a report on Wednesday, July 24th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $60.71.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.